📉Lower LDL-C for longer is better. The NLA’s new guidance simplifies LDL-C management for adults — helping clinicians & patients improve evidence-based measurement and treatment of LDL-C. Read the guidelines & recommendations: lipidjournal.com/article/S1933-…. Beth Jackson Christie Ballantyne

🔰Ecogenicidad de las placas carotídeas como predictor de regresión tras la terapia hipolipemiante.🇨🇳 ✅️ 838 pacientes con placas carotídeas que recibían terapia hipolipemiante se inscribieron entre julio de 2020 y mayo de 2024 y fueron seguidos durante 12 meses. ✅️Las

TERAPIA HIPOLIPEMIANTE COMBINADA EN PACIENTES DE ALTO RIESGO CARDIOVASCULAR 🫀 Parece una estrategia más razonable 🧐 Terapia combinada 🆚 estatinas en altas dosis -Mayor ⬇️ de LDL-c -Mayor ⬇️de eventos CV -Menor suspensión o ⬇️ de dosis Vía European Society of Cardiology Journals academic.oup.com/cardiovascres/…

La diabetes gestacional representa un marcador de salud Cardiovascular previo al embarazo y enfatiza la importancia de mejorarla precozmente antes del embarazo - Prepregnancy Cardiovascular Health, Gestational Diabetes, and Coronary Artery Calcium jamanetwork.com/journals/jamac…

A must-read in the field of cardiovascular prevention: “Residual cardiovascular risk beyond LDL-C: inflammation, remnant cholesterol, and lipoprotein(a)” by Anders Wulff and Prof. Børge Nordestgaard, just published in the European Heart Journal (2025). This editorial

🗣️Orticumab: the potential to harness oxidized LDL to reduce coronary inflammation with plaque-targeted therapy ▶️El tratamiento con orticumab representa una forma nueva y específica de reducir la inflamación arterial journals.lww.com/co-lipidology/… LipidoSEEN

🤔If high LDL cholesterol is so dangerous… why doesn’t it hurt? ☝️Because evolution doesn’t care if you drop dead after you’ve reproduced. 👉LDL cholesterol is a silent killer—causal, cumulative, and completely asymptomatic. You won’t feel your arteries clogging. You won’t

🔰Una ecuación de Sampson-NIH modificada con mayor precisión para estimar niveles bajos de C-LDL. 👏Que gran trabajo de Rafael Zubirán y sus colegas, utilizando los resultados de las pruebas del panel lipídico de la Clínica Mayo y el ensayo clínico FOURIER, realizaron una ecuación

⭐️¿Y si una molécula producida por tu microbiota intestinal pudiera causar aterosclerosis sin alterar el colesterol? Eso sugiere un nuevo estudio en Nature 👇 🔗 nature.com/articles/s4158… Investigadores identifican el imidazol propionato (ImP) como un metabolito microbiano

🔬 Nuevo análisis del FOURIER trial comentado por el Dr. Gimeno-Orna: 👉 En pacientes con ECV y EAI, la reducción intensiva de cLDL con iPCSK9 aporta mayor beneficio relativo y absoluto. ✅ Refuerza la sinergia entre inflamación e hiperlipemia. 👉 seen.es/blog/lipidos-y…

The BMI is a marker of total body mass and not a specific marker of adipose tissue mass. Relative fat mass #RFM is an alternative to BMI with superior performance of RFM in assessing cardiometabolic risk. nature.com/articles/s4157…

🔴🔴Lilly's Mounjaro (tirzepatide), a GIP/GLP-1 dual agonist, demonstrated CV protection in patients with type 2 diabetes and heart disease 👍Mounjaro met the primary objective of non-inferiority vs. Trulicity with an 8% lower rate of MACE-3 events, while delivering greater

👉Cholesterol Crystals: Not Just a Marker — A Causal Trigger of Vascular Inflammation ☝️A growing body of evidence highlights cholesterol crystals (CCs) as active drivers—not mere bystanders—in the pathogenesis of atherosclerosis. ☝️CCs initiate a cascade of inflammatory events

📕Can small dense LDL cholesterol be estimated from the lipid profile? 👉La estimación del c-LDLd estimado presenta una alternativa prometedora a la medición directa journals.lww.com/co-lipidology/… LipidoSEEN

Lp(a) as a Prognostic Marker of ASCVD Progression New study with 460k participants showed that: 1️⃣ Median Lp(a) Levels: 1) No Vascular Disease: 19.5 nmol/L 2) Incident PAD: 25.3 nmol/L 3) PAD to MALE: 33.3 nmol/L 4) Incident Carotid Stenosis: 29.5 nmol/L 5) Carotid Stenosis to

INTERVENCIONES EN ESTILO DE VIDA EN PREVENCIÓN Y MANEJO DEL SÍNDROME CARDIO-RENO-METABÓLICO Vía JACC Journals jacc.org/doi/10.1016/j.…

Promising Drugs For Lp(a) Reduction Five drugs in development that lower Lp(a) concentrations by 65-98%: 1️⃣ Muvalaplin: 65% 2️⃣ Pelacarsen: 80% 3️⃣ Olpasiran: 98% 4️⃣ Zerlasiran: 98% 5️⃣ Lepodisiran: 98% Thomas Dayspring Dr. Spencer Nadolsky Karl Nadolsky Gil Carvalho MD PhD🌈🇵🇸 Matthew Nagra, ND

Lipoprotein(a) Doesn’t Budge: New Atherosclerosis study (Koller et al., 2025) shows Lp(a) levels stay remarkably stable over 3.2 yrs. -✅ 91.6% stayed in same risk category -⚠️ Variability mostly due to lab error, not biology Link➡️ atherosclerosis-journal.com/action/showPdf… European Atherosclerosis Society

CONFIDENCE trial: In persons with chronic kidney disease and type 2 diabetes, combination therapy with finerenone and empagliflozin led to a greater reduction in the urinary albumin-to-creatinine ratio than either drug alone. Full trial results and Research Summary:

Coadministered Cagrilintide and Semaglutide in Adults with Overweight or Obesity | New England Journal of Medicine nejm.org/do/10.1056/NEJ…